Highest-materiality recent filing
Valion Bio shareholders approve 2.58M share increase to 2021 equity plan; Dean Zikria re-elected
Shareholders approved a 2,581,608 share increase under the 2021 Equity Incentive Plan (736,919 for, 134,918 against).
Valion Bio posts Q1 net loss of $6.2M; cash falls to $7.2M; advances Entolimod
Net loss $6.2M ($2.23/share) vs $1.5M ($2.52/share) a year ago; operating expenses $5.6M (was $1.4M).
Valion Bio appoints Melinda Lackey as General Counsel and SVP of Legal Affairs
Melinda Lackey, age 49, appointed as GC and SVP of Legal Affairs, effective May 4, 2026.
Tivic Health rebrands as Valion Bio; ticker to VBIO; targets BARDA SNS procurement for Entolimod
Corporate name changes to Valion Bio, Inc.; Nasdaq ticker to change from TIVC to VBIO effective April 28, 2026.
Tivic reports FY2025 net loss $8.8M-$9.1M; pivots to immunotherapy with Entolimod
Operating expenses $7.9M in 2025 vs $4.5M in 2024; net loss before disc. ops $7.9M-$8.1M.
Tivic Health receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Received Nasdaq notification on March 19, 2026 for bid price below $1.00 for 30 consecutive business days.
Tivic Health subsidiary Velocity Bioworks signs three facility leases totalling ~$11.6M base rent
Microbial Building Lease: 8,024 sq ft, 8-year term, $5.34M aggregate base rent; option to purchase for $12.5M within first 24 months.
Special meeting held Feb 19, 2026 adjourned due to lack of quorum; less than one-third of shares present.
Tivic Health CEO Jennifer Ernst resigns; Michael Handley appointed CEO to lead biopharma pivot
CEO Jennifer Ernst resigned March 2, 2026; board departure effective March 5; separation includes $325K cash severance, COBRA, equity vesting, and $50K restricted stock.
Tivic Health files Scorpius audited financials; FY2024 net loss $32.8M on $6.2M revenue
Scorpius FY2024 revenue $6.24M, net loss $32.8M; auditor BDO flags going-concern doubt due to recurring losses.
Tivic Health enters $50M equity line with Tumim Stone Capital; pre-funded warrant issued
Common Stock Purchase Agreement allows Tivic to sell up to $50M of common stock to Tumim Stone Capital at 97% or 95% of VWAP.
Company targeting multiple high-value inflection points expected within the next 18-24 months.
Tivic Health acquires Scorpius CDMO assets and closes $16.25M note and $12M preferred offerings
Acquired Scorpius CDMO assets for $16.25M cash via Article 9 sale through subsidiary Velocity Bioworks.
Tivic Health secures BARDA Techwatch meeting for Entolimod ARS program
Meeting with BARDA's Radiological and Nuclear Medical Countermeasures Program staff to discuss Entolimod for acute radiation syndrome.
Tivic Health winds down ClearUP consumer biz; Q3 net loss $2.6M
Q3 revenue $146K (+16% YoY); gross loss $145K from $230K inventory reserve for ClearUP exit.
Tivic Health study: personalized ncVNS boosts HRV 46%, 8.9x vs fixed frequency
Personalizing stimulation frequency increased heart rate variability by 46%, 8.9x more effective than uniform frequency across subjects.
Tivic Health enters new CEO employment agreement with Jennifer Ernst; base salary $325K
Jennifer Ernst, CEO, enters new employment agreement effective Oct 8, 2025, replacing prior offer letter.
Effective August 30, 2025, Odyssey Transfer and Trust replaces Equiniti as transfer agent and registrar.
Tivic Health receives two INDs for Entolimod from Statera for ARS and advanced cancers
Completed transfer of two INDs from Statera Biopharma for lead candidate Entolimod.
Revenue $86k (-39% YoY); net loss $1.9M vs $1.3M in Q2 2024; cash $1.2M at June 30.
Tivic Health amends license deal with Statera; royalties payable in stock; lien up to $5.6M
Royalties may be paid in cash or Tivic securities at Tivic's discretion under the A&R License Agreement.
Lisa Wolf appointed permanent CFO effective July 7, 2025; base salary $240,000 plus bonus up to 35% of base.
Tivic Health completes Optimization Study for ncVNS device; results due later in 2025
All study visits completed for patent-pending non-invasive cervical vagus nerve stimulation device.
Amended license agreement gives Tivic discretion to pay future royalties in cash or its own securities.
Tivic Health furnishes Sidoti conference presentation; exhibit content not fully provided
CEO Jennifer Ernst to present at Sidoti Micro Cap Conference on May 22, 2025.
Tivic Health sets 2025 Annual Meeting for June 30; updates shareholder proposal deadlines
Annual Meeting to be held virtually on June 30, 2025; record date May 14, 2025.
Tivic Health Q1 revenue drops 79% to $70K; pursues Entolimod and ncVNS pipeline
Revenue fell 79% YoY to $70K; net loss unchanged at $1.5M. Cash $669K vs $2.0M at year-end.
Tivic Health enters $4.1M GMP manufacturing agreement with Scorpius for Entolimod ARS
Scorpius BioManufacturing to perform GMP validation for Entolimod, a TLR5 agonist for Acute Radiation Syndrome (ARS).
Tivic Health enters up to $8.4M Series B Preferred financing with Helena Global
Up to $8.4M from sale of Series B Non-Voting Convertible Preferred at $1,000/share plus warrants for common stock.
Tivic Health briefed White House and FDA on TLR5 candidates and ncVNS; positive interest noted
On April 17, 2025, briefed White House senior leadership on Entolimod for acute radiation syndrome and need for advanced treatments.
Tivic Health adds $1.77M baby shelf capacity under existing Equity Distribution Agreement
Company may sell up to $1,767,913 in common stock through Maxim Group under updated prospectus supplement.
Tivic Health regains Nasdaq minimum bid price compliance; stock continues listing
Received Nasdaq confirmation on April 4, 2025 that minimum bid price compliance is regained.
Tivic Health exercises option for Neutropenia license; accelerates $500K milestone
Exercised Exclusive Option on March 28, 2025 to license Neutropenia indication of Entolimod from Statera.
Tivic Health FY2024 net loss narrows to $5.7M; secures $25M equity line, in-licenses Entolimod
FY2024 revenue $0.8M (down from $1.2M); net loss -$5.7M vs -$8.2M in 2023 (30% decrease).
Tivic Health presents data showing personalized VNS nearly doubles HRV in 60% of participants
Data from Feinstein Institute collaboration presented at Sixth Bioelectronic Medicine Summit.
Reverse split at 1:17 ratio; effective 12:01 a.m. ET on March 7, 2025.
Tivic Health names Michael Handley COO and President of Tivic Biopharma following Statera license
Handley appointed COO and President of new Tivic Biopharma division, effective Feb 18, 2025.
Tivic Health acquires exclusive worldwide license for Statera's TLR5 agonist Entolimod for ARS
License fee of $1.5M ($300K cash + $1.2M in stock and preferred) for exclusive rights to Entolimod for ARS.
Tivic Health shareholders approve reverse stock split authorization (1:2 to 1:30)
Reverse split ratio range authorized: 1-for-2 to 1-for-30, at board discretion within 12 months.
Tivic Health receives Nasdaq delisting notice; hearing requested, reverse split proposed
Nasdaq notified Tivic on Dec 27, 2024 it failed to regain $1.00 bid price compliance and is ineligible for a second 180-day period due to equity deficiency.
Tivic Health reports >65% DTC gross margin, advances VNS program with Feinstein Institute
ClearUP 2.0 launched; McKesson & Cardinal Health partnerships accelerating; customer reviews 4.4 stars; defect returns down.
Tivic Health Q3 revenue $126K, down 27% YoY; net loss narrows to $1.4M
Revenue for nine months ended Sep 30, 2024: $600K, down 27% vs 2023 on 36% fewer units sold.
Tivic Health receives IRB approval from Feinstein Institutes for ncVNS optimization study
Received IRB approval from Feinstein Institutes for clinical optimization study of ncVNS; enrollment to commence.
Tivic Health Partners with Fletcher Spaght to Accelerate ncVNS Commercial Strategy
Partnered with Fletcher Spaght, a healthcare growth strategy firm, to develop commercial strategy for non-invasive cervical vagus nerve stimulation (ncVNS).
Tivic Health enters ATM equity facility up to $10M; appoints Lisa Wolf as interim CFO
Equity Distribution Agreement with Maxim Group for at-the-market sales of common stock up to $10M aggregate offering price; current baby shelf limit $1.44M.
Tivic Health Q2 2024 revenue $140K, net loss $1.3M; Phase 1 VNS results, cost cuts
Q2 2024 revenue $140K vs $203K in Q2 2023; H1 2024 revenue $474K, down 12% YoY.
Tivic Health stockholders approve 10x increase in equity plan shares to 1M
A&R Plan approved, increasing authorized shares from 92,376 to 1,000,000 (over 10x increase).
Tivic Health terminates ALOM fulfillment agreement to reduce costs, transitions to in-house ops
Effective August 1, 2024, terminated ALOM Fulfillment Services Agreement for convenience; no material early termination penalties.
Tivic Health receives Nasdaq delisting notice for bid price below $1.00 for 33 days
Received Nasdaq deficiency letter on June 28, 2024 for non-compliance with minimum bid price requirement.
Tivic Health appoints Christina Valauri to board; Karen Drexler resigns effective Sep 30
Christina Valauri appointed director effective July 1, 2024; will chair Nominations & Corp Gov Committee.
On May 4, 2026, Melinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs of Valion Bio, Inc.
On February 18, 2025, Michael Handley was appointed as Chief Operating Officer of Tivic Health Systems, Inc., a Delaware corporation (the “Company”), and President of the Company’s Tivic Biopharma division.
On September 12, 2024, Kimberly Bambach tendered her resignation from her role as interim Chief Financial Officer of the Company, effective October 1, 2024.
Effective October 1, 2024, Lisa Wolf has been appointed as the Company’s new interim Chief Financial Officer and Principal Financial and Principal Accounting Officer.
On June 17, 2024, Karen Drexler tendered her resignation from the Board and each of the Compensation Committee, Audit and Risk Committee and Nominations and Corporate Governance Committee thereof, in each case effective September 30, 2024.
On June 17, 2024, the board of directors (the “Board”) of Tivic Health Systems, Inc. (the “Company”) appointed Christina Valauri as a director of the Company, effective July 1, 2024
Max materiality 0.90 · Median 0.65 · Most common event other_material